ReviewJournal of cancer research and clinical oncology2022
Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world.
Review in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pooled it
- Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.International urology and nephrology · 2026Article
- Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature.Journal of clinical medicine · 2026Review
- New therapies, new challenges: Cystic lung disease after cancer immunotherapy.Respiratory medicine case reports · 2026Article
- Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system.Frontiers in immunology · 2026Article
- Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study.Frontiers in immunology · 2026Article
- Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database.Drugs - real world outcomes · 2025Article
- [Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Navigating Drug-Induced Lung Disease (DILD): A Comprehensive Review on Management and Prevention Strategies.Cureus · 2024Review
- The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review.Insights into imaging · 2024Review
- Usefulness of Quantification and Serial Monitoring of Fine Crackles for Early Detection of Treatment-related Lung Injury: A Report of Two Cases.Internal medicine (Tokyo, Japan) · 2024Article
- Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.Respiratory research · 2024Article
- Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease.Frontiers in pharmacology · 2023Article
- Temporal Trends in Antineoplastic Agent-associated Interstitial Lung Disease Involving Immune Checkpoint Inhibitors in the JADER Database.In vivo (Athens, Greece)Article
- Interstitial lung disease associated with novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInvestigate the frequency and prognostic factors of severe drug-induced interstitial lung disease (DILD) caused by antineoplastic drugs regardless of cancer types or type of drugs.
methodsFrom 2014 to 2018, we reviewed patients with a history of antineoplastic agents administration in the real-world database of our hospital's electronic medical record and extracted patients who experienced "severe" DILD, requiring hospitalization with treatment or developed during hospitalization and required treatment. We collected patients' backgrounds, clinical and radiological features, laboratory data, treatment, and survival outcomes.
results19,132 cancer patients received antineoplastic drug therapy during the study period, and 120 (0.62%) experienced severe DILD. The incidence of severe DILD in patients with thoracic cancer was highest among the patients included in this analysis (2.52% vs. 0.34% other cancers). Diffuse alveolar damage (DAD) pattern on CT was associated with higher mortality in patients with severe DILD compared with non-DAD pattern (hazard ratio [HR], 11.24; 95% CI, 4.82-26.2). Multivariate analysis revealed that the DAD pattern at diagnosis as severe DILD (HR, 3.59; 95% CI, 1.17-11.03), concurrent/previous interstitial lung disease (HR, 3.20; 95% CI, 1.27-8.10), and ECOG performance status of 2-4 (HR, 3.81; 95% CI, 1.10-13.17) were independent risk factors for mortality in patients with severe DILD.
conclusionsThe frequency of severe DILD was highest in patients with thoracic cancer. The DAD pattern was associated with a poor outcome. From the perspective of DILD, special attention should be paid when administering antineoplastic agents to patients with thoracic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.